FDA
-
-
-
-
-
-
-
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
-
-
-
-
-
-
-
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
BofA Securities Downgrades Arvinas Inc. (ARVN) to Neutral
-
-
-
-
-
-
-
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
-
-
-
-
-
-
-
Arvinas (ARVN) Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology
-
-
-
-
-
-
-
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
-
-
-
-
-
-
-
HOOKIPA Pharma Inc. (HOOK) Announces Leadership Changes to Intensify Focus on HB-200
-
327,748 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

